Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 781 to 790 of 1334 total matches.

Alpha-Galactosidase to Prevent Gas

   
The Medical Letter on Drugs and Therapeutics • Apr 02, 1993  (Issue 893)
galactosidase units of enzymatic activity. Medical Letter consultants believe that this amount of αgalactosidase ...
The enzyme alpha-galactosidase (Beano - AkPharma), derived from a mold and classified as a food, is sold without presecription in pharmacies and food stores. The manufacturer recommends taking the anzyme to decrease intestinal gas producted by eating the high-fiber diets now widely recommended in the USA.
Med Lett Drugs Ther. 1993 Apr 2;35(893):29-30 |  Show IntroductionHide Introduction

Shade UVAGuard - A Second Broad-Spectrum Sunscreen

   
The Medical Letter on Drugs and Therapeutics • Jun 11, 1993  (Issue 898)
; avobenzone is active against longer UVA wavelengths. The absorption spectra of the broad-spectrum sunscreens ...
In 1989, Photoplex (Allergan Herbert), a combination of the dibenzoyl methane avobenzone (Parsol 1789) and the aminobenzoic acid (PABA) ester padimate O, was the first 'broad spectrum' sunscreen to become available in the USA (Medical Letter, 31:59, 1989). Now, Shade UVAGuard (Schering-Plough), a similar product, has been approved by the US Food and Drug Administration; it also contains avobenzone, plus the benzophenone oxybenzone and octyl methoxycinnamate.
Med Lett Drugs Ther. 1993 Jun 11;35(898):53-4 |  Show IntroductionHide Introduction

Radioactive Strontium-89 for Painful Bone Metastases

   
The Medical Letter on Drugs and Therapeutics • Oct 29, 1993  (Issue 908)
(SL Breen et al, J Nucl Med, 33:1316, 1992). Bone uptake is greatest in areas of active osteogenesis ...
Strontium-89 chloride was recently approved for marketing by the US Food and Drug Administration. It is offered for relief of pain caused by metastatic bone lesions
Med Lett Drugs Ther. 1993 Oct 29;35(908):102 |  Show IntroductionHide Introduction

Abciximab to Prevent Vessel Closure After Angioplasty

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 1995  (Issue 950)
) to the surface of activated platelets (BS Coller, N Engl J Med, 322:33, 1990). PHARMACOKINETICS — In most ...
Abciximab (ab sik si mab; ReoPro - Centocor), the Fab (fragment antigen binding) fragment of the chimeric human-murine monoclonal antibody 7E3 (c7E3 Fab), has been approved by the US Food and Drug Administration as an adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA) to prevent abrupt closure of the treated coronary vessel.
Med Lett Drugs Ther. 1995 Jun 9;37(950):52-3 |  Show IntroductionHide Introduction

Simethicone for Gastrointestinal gas

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996  (Issue 977)
bloating. According to a recent press release, "Phazyme works fast so people can continue living active ...
Gastrointestinal gas may cause symptoms when excessive amounts become trapped in the stomach and intestinal tract. Simethicone (Gas-X, Maalox Anti-Gas, Mylanta Gas Relief, Mylicon, Phazyme), sold over-the-counter in capsules, tablets and infant drop formulations, is being heavily advertised to the public for symptomatic treatment of flatulence and gastric bloating. According to a recent press release, 'Phazyme works fast so people can continue living active lives and eating the foods they love without fear of embarrassment.' Products that combine one or more antacids with simethicone...
Med Lett Drugs Ther. 1996 Jun 21;38(977):57-8 |  Show IntroductionHide Introduction

Glatiramer Acetate for Relapsing Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Jul 04, 1997  (Issue 1004)
proteins to major histocompatibility complex molecules, leading to suppression of T-cell activation ...
Glatiramer acetate (Copaxone - Teva Marion Partners), formerly known as copolymer-l, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (MS). Interferon β-1b (Betaseron) and interferon β-1a (Avonex - Medical Letter, 38:63, 1996) were previously approved for this indication.
Med Lett Drugs Ther. 1997 Jul 4;39(1004):61-2 |  Show IntroductionHide Introduction

Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • May 08, 1998  (Issue 1026)
and in the liver to hydrodolasetron, an active metabolite that is further metabolized in the liver by CYP2D6 ...
Dolasetron (Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT3) receptor antagonist similar to ondansetron (Zofran) and granisetron (Kytril - Medical Letter, 36:61, 1994) is now available for both oral and intravenous use in prevention of nausea and vomiting due to cancer chemotherapy. A 5-HT3 antagonist plus dexamethasone (Decadron, and others) is the most effective regimen for prevention of acute vomiting caused by cancer chemotherapy. Dolasetron has also been approved by the FDA for prevention and treatment of postoperative nausea and...
Med Lett Drugs Ther. 1998 May 8;40(1026):53-4 |  Show IntroductionHide Introduction

Temozolomide for Refractory Anaplastic Astrocytoma

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 1999  (Issue 1068)
Yung et al, J Clin Oncol, 17:2762, Sept 1999). Temozolomide has shown antitumor activity in melanoma ...
Temozolomide has received accelerated approval from the FDA for oral treatment of adults with anaplastic astrocytoma that has relapsed after treatment with a nitrosourea (lomustine or carmustine) and procarbazine.
Med Lett Drugs Ther. 1999 Dec 17;41(1068):123-4 |  Show IntroductionHide Introduction

Once-a-week Alendronate (Fosamax)

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001  (Issue 1100)
bone resorption. The drugs remain active in bone for several weeks. The main drawback of daily ...
Once-a-week formulations of alendronate (Fosamax) in 35- and 70-mg tablets have now been approved by the FDA and are being heavily promoted for prevention and treatment of postmenopausal osteoporosis. A new formulation of risedronate (Actonel) for once-a-week use is under development and may be available next year.
Med Lett Drugs Ther. 2001 Mar 19;43(1100):26 |  Show IntroductionHide Introduction

Once-Daily Gabapentin (Gralise) for Postherpetic Neuralgia

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2011  (Issue 1378)
with placebo in 452 patients with PHN for at least 6 months. Those treated with the active drug had ...
A new once-daily formulation of gabapentin (Gralise – Depomed) has been approved by the FDA for treatment of postherpetic neuralgia (PHN). Immediate-release (IR) gabapentin (Neurontin, and others), which has been available in the US since 1994, is also approved for this indication, but is taken three times a day. Extended-release gabapentin enacarbil (Horizant) was recently approved by the FDA for treatment of restless legs syndrome.
Med Lett Drugs Ther. 2011 Nov 28;53(1378):94 |  Show IntroductionHide Introduction